Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug PHN-012 takes aim at Hard-to-Treat cancers

NCT ID NCT07127874

Disease control Sponsor: Pheon Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, while also seeing if it can shrink tumors or slow disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has histologically confirmed, advanced/metastatic: 1. Colorectal adenocarcinoma (CRC), or 2. Non-small cell lung cancer (NSCLC), or 3. Pancreatic ductal adenocarcinoma (PDAC). * Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy. * Has measurable disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Has adequate organ function. * Has available tumor tissue sample at screening (either an archival specimen or fresh biopsy material). Exclusion Criteria: * Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload. * Has unstable central nervous system metastasis. * Has persistent toxicities from previous systemic anti-cancer treatments of Grade \>1. * Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug. * Has received wide-field radiotherapy (\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention. * Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention. * Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic steroids within 6 months prior to first dose of the study drug, active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma colon carcinoma colonic neoplasm colorectal adenocarcinoma lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Advanced solid tumors Colon cancer Lung cancer (NSCLC) Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    26 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • PHN-012-001 Site

    RECRUITING

    Los Angeles, California, 90033, United States

  • PHN-012-001 Site

    RECRUITING

    San Diego, California, 92037, United States

  • PHN-012-001 Site

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • PHN-012-001 Site

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • PHN-012-001 Site

    RECRUITING

    St Louis, Missouri, 63108, United States

  • PHN-012-001 Site

    RECRUITING

    Durham, North Carolina, 27710, United States

  • PHN-012-001 Site

    RECRUITING

    Portland, Oregon, 97239, United States

  • PHN-012-001 Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • PHN-012-001 Site

    RECRUITING

    Houston, Texas, 77030, United States

  • PHN-012-001 Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • PHN-012-001 Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Seoul, Gangnam-gu, 06351, South Korea

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • PHN-012-001 Site

    RECRUITING

    Seoul, Jongno-gu, 03080, South Korea

  • PHN-012-001 Site

    RECRUITING

    Seoul, Seodaemun-gu, 03722, South Korea

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Seoul, Seoucho-gu, 06591, South Korea

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Seoul, Songpa-gu, 05505, South Korea

  • PHN-012-001 Site

    RECRUITING

    Barcelona, Community of Catalonia, 08023, Spain

  • PHN-012-001 Site

    RECRUITING

    Barcelona, Community of Catalonia, 08035, Spain

  • PHN-012-001 Site

    NOT_YET_RECRUITING

    Madrid, Madrid, 28007, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28027, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • PHN-012-001 Site

    RECRUITING

    Madrid, Madrid, 28050, Spain

  • PHN-012-001 Site

    RECRUITING

    Valencia, Valencia, 46009, Spain

  • PHN-012-001 Site

    RECRUITING

    Valencia, Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.